BioCentury | Sep 14, 2020
Deals

High takeout premium in $21B deal shows Gilead’s confidence in value of Immunomedics’ ADC

For Gilead to derive value commensurate with the $21 billion it will pay to buy Immunomedics at more than double the biotech’s market cap, its first-in-class antibody-drug conjugate Trodelvy will have...
BioCentury | Sep 1, 2020
Deals

Gilead deal clears path for Jounce to advance immuno-oncology programs

Via a deal with Gilead yielding $120 million in upfront cash for rights to a preclinical oncology program, Jounce will extend its cash runway into 2023 as it presses forward with a lead program on...
BioCentury | Aug 7, 2020
Deals

Survey: sweet spots and vulnerabilities for dealmaking in the COVID era

Heading into the second half of the year with cautious optimism, drug developers see opportunities for dealmaking created by COVID-19, as well as challenges. If their predictions are right, infectious deals could surpass cancer transactions....
BioCentury | Jun 24, 2020
Deals

Data Bytes: Gilead’s 2020 cancer deals take on immuno-oncology from different angles

Gilead Sciences has partnered with or acquired five cancer companies in the past four months, with each deal anchored by a different approach to immuno-oncology. The biotech’s largest deal -- a $4.9 billion acquisition of...
BioCentury | Jun 24, 2020
Deals

Gilead gains access to tumor myeloid targets via Pionyr partnership

Gilead’s tie-up with Pionyr marks the big biotech’s fifth cancer deal this year and gives it access to mAbs against immunosuppressive tumor myeloid cells. In an agreement announced Tuesday, Gilead Sciences Inc. (NASDAQ:GILD) will pay...
BioCentury | Apr 17, 2020
Product Development

BARDA’s $483M commitment to Moderna headlines flurry of COVID-19 vaccine updates

...adjuvant include collaborations between Sinovac Biotech Ltd. (NASDAQ:SVA) and Dynavax Technologies Corp. (NASDAQ:DVAX), and between Soligenix Inc....
...in China on Tuesday, along with the Sinopharm unit of China National Biotech Group Corp. Soligenix...
...and Sandi Wong, Assistant Editor mRNA-1273 Moderna Inc. Inovio Pharmaceuticals Inc. Coalition for Epidemic Preparedness Innovations Sinovac Biotech Ltd. Dynavax Technologies Corp. Soligenix Inc. Boston...
BioCentury | Feb 21, 2020
Finance

Food allergy company Alladapt raises $60M series C led by Viehbacher's Gurnet Point

With $60 million in a new series C round, Alladapt will test its broad-spectrum immunotherapy approach to treat a broad swath of food allergies in its first clinical trial beginning this year. Gurnet Point Capital...
BioCentury | Aug 1, 2019
Financial News

Vida seeking bigger deals, cures with $600M fund

As Vida Ventures prepares to deploy its $600 million second fund, the firm believes its larger investments in biotech megarounds can continue to be good bets. Vida, whose team includes several former members of Kite...
BioCentury | Jan 16, 2019
Distillery Therapeutics

Cancer

...Next steps could include testing the compound in patient-derived xenograft (PDX) mouse model of glioblastoma. Soligenix Inc....
BioCentury | Jan 5, 2019
Finance

Ready to launch

...2Q19 Sesen Bio Inc. (NASDAQ:SESN) Vicinium Non-muscle invasive bladder cancer (NMIBC) Phase III data Mid-2019 Soligenix Inc....
Items per page:
1 - 10 of 421
BioCentury | Sep 14, 2020
Deals

High takeout premium in $21B deal shows Gilead’s confidence in value of Immunomedics’ ADC

For Gilead to derive value commensurate with the $21 billion it will pay to buy Immunomedics at more than double the biotech’s market cap, its first-in-class antibody-drug conjugate Trodelvy will have...
BioCentury | Sep 1, 2020
Deals

Gilead deal clears path for Jounce to advance immuno-oncology programs

Via a deal with Gilead yielding $120 million in upfront cash for rights to a preclinical oncology program, Jounce will extend its cash runway into 2023 as it presses forward with a lead program on...
BioCentury | Aug 7, 2020
Deals

Survey: sweet spots and vulnerabilities for dealmaking in the COVID era

Heading into the second half of the year with cautious optimism, drug developers see opportunities for dealmaking created by COVID-19, as well as challenges. If their predictions are right, infectious deals could surpass cancer transactions....
BioCentury | Jun 24, 2020
Deals

Data Bytes: Gilead’s 2020 cancer deals take on immuno-oncology from different angles

Gilead Sciences has partnered with or acquired five cancer companies in the past four months, with each deal anchored by a different approach to immuno-oncology. The biotech’s largest deal -- a $4.9 billion acquisition of...
BioCentury | Jun 24, 2020
Deals

Gilead gains access to tumor myeloid targets via Pionyr partnership

Gilead’s tie-up with Pionyr marks the big biotech’s fifth cancer deal this year and gives it access to mAbs against immunosuppressive tumor myeloid cells. In an agreement announced Tuesday, Gilead Sciences Inc. (NASDAQ:GILD) will pay...
BioCentury | Apr 17, 2020
Product Development

BARDA’s $483M commitment to Moderna headlines flurry of COVID-19 vaccine updates

...adjuvant include collaborations between Sinovac Biotech Ltd. (NASDAQ:SVA) and Dynavax Technologies Corp. (NASDAQ:DVAX), and between Soligenix Inc....
...in China on Tuesday, along with the Sinopharm unit of China National Biotech Group Corp. Soligenix...
...and Sandi Wong, Assistant Editor mRNA-1273 Moderna Inc. Inovio Pharmaceuticals Inc. Coalition for Epidemic Preparedness Innovations Sinovac Biotech Ltd. Dynavax Technologies Corp. Soligenix Inc. Boston...
BioCentury | Feb 21, 2020
Finance

Food allergy company Alladapt raises $60M series C led by Viehbacher's Gurnet Point

With $60 million in a new series C round, Alladapt will test its broad-spectrum immunotherapy approach to treat a broad swath of food allergies in its first clinical trial beginning this year. Gurnet Point Capital...
BioCentury | Aug 1, 2019
Financial News

Vida seeking bigger deals, cures with $600M fund

As Vida Ventures prepares to deploy its $600 million second fund, the firm believes its larger investments in biotech megarounds can continue to be good bets. Vida, whose team includes several former members of Kite...
BioCentury | Jan 16, 2019
Distillery Therapeutics

Cancer

...Next steps could include testing the compound in patient-derived xenograft (PDX) mouse model of glioblastoma. Soligenix Inc....
BioCentury | Jan 5, 2019
Finance

Ready to launch

...2Q19 Sesen Bio Inc. (NASDAQ:SESN) Vicinium Non-muscle invasive bladder cancer (NMIBC) Phase III data Mid-2019 Soligenix Inc....
Items per page:
1 - 10 of 421